Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. Article (PDF Available) in New England Journal of Medicine. The primary outcome was the time to monotherapy failure, which was defined as a Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. FPrime Recommended Article: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

Author: Vigis Taugul
Country: Bolivia
Language: English (Spanish)
Genre: Video
Published (Last): 25 January 2015
Pages: 112
PDF File Size: 10.28 Mb
ePub File Size: 5.16 Mb
ISBN: 292-6-17209-414-7
Downloads: 47856
Price: Free* [*Free Regsitration Required]
Uploader: Kajit

Nat Clin Pract Endocrinol Metab. Related articles in Web of Science Google Scholar.

The primary outcome was the time to monotherapy failure, which was defined as a confirmed level of fasting plasma glucose of more than mg per deciliter The patients were treated for a median of 4. In contrast to the recent DREAM trial, which showed a dramatic efficacy of rosiglitazone to delay glycemic progression in prediabetes that was accompanied by a surprising incidence of congestive heart failure 13there was no increase in nonadjudicated congestive heart failure Mlnotherapy with rosiglitazone compared with metformin in ADOPT.

Copyright Massachusetts Medical Society. New England Journal of MedicineVol. King’s College London King’s main site.

Glycdmic does not claim any ownership in the Material that you or any other user posts. N Engl J Med. Pleiotropic effects of thiazolidinediones. Interestingly, metformin exhibited reasonable insulin-sensitizing effects although not as robust as rosiglitazonean effect that has not been consistently shown in prior metformin trials.

By clicking “I accept the Terms and Conditions relating to Materials” before you submit your first Material as hereinafter defined you agree to be bound by these conditions every time you submit Material. Failure to metformin and insulin secretagogue monotherapy: From This Paper Figures, tables, and topics from this paper. The mean dose of each monotherapy given to the patients in ADOPT was not reported, and it will be instructive to learn this parameter in the future.


F reserves the right to remove any comments that it considers in its absolute discretion to be inappropriate, offensive or otherwise in breach of the Terms and Conditions relating to Materials including Comments. Fifty years after the first description, the MEN 2B syndrome diagnosis is still mefformin This paper has highly influenced 73 other papers. The potential risks and benefits, the profile of adverse events, and the eurability of these three drugs should metformiin be considered to help inform the choice of pharmacotherapy for patients with type 2 diabetes.

Any view or opinion expressed in any Material is the view or opinion of the person who posts such view or opinion. Pharmacotherapy of type 2 diabetes: Considering the large number of subjects and the duration of blinded therapy in this landmark trial, however, ADOPT provides a superior level of confidence in its assessment of the monotherapy performance of these drugs compared with data from smaller previous studies of shorter duration. Brancati Annals of internal medicine Glycemic control from to among U.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

The patients were treated for a median of 4. View graph of relations. Citations Publications citing this paper.

Methods We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving rosigoitazone. Sign In or Create an Account. Antihyperglycemic activity with molecular docking study. You are an Editor for the journal in which the article is published.

A summary of the content will be automatically included. Results of a Randomized Controlled Trial.

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. – FPrime

Disclosures Gljburide Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy PolicyTerms of Serviceand Dataset License. This paper has been referenced on Twitter 1 time over the past 90 days.


You are entitled to post or upload the Material on the website and have all necessary licenses and consents to do so; the Material does not infringe any intellectual property right, including without limitation copyright, patent or trademark, or other proprietary right of any third party; the Material does not contain any defamatory, libellous, offensive, indecent or otherwise unlawful material or material which is an invasion of privacy; the Material does not contain any contaminating or destructive features or devices such as viruses, time bombs or coding designed to interrupt, destroy or limit the functionality of this website or any of this website’s user’s computer equipment or software; the Material will not be used to solicit or promote business or custom or present commercial activities or unlawful activity; and the Material is in compliance with all applicable laws.

F does not store recipient email addresses. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.

Consider the following examples, but note that this is not an exhaustive list:. Accordingly you may only post Material that you have the right to do so. Material does not reflect the views or opinions of F, its agents or affiliates. The growing availability of fixed-drug-combination pills of this type will also significantly help to contain costs and simplify patient regimens.